| 2022-LOW-69573 | |
| NCS: Researchers at Purdue University have discovered a method to rejuvenate exhausted chimeric antigen receptor (CAR) T cells to treat cancers. CAR T cells have shown promise in hematologic cancer treatment, however, their application in eradication of solid tumors remains limited by their development of a dysfunctional or exhausted phenotype, leading to decreased proliferation of CAR T cells and compromised effector function. By targeting ligands of the fluorescein receptor and Toll-like receptor 7/8 (TLR7/8), the Purdue researchers rejuvenated exhausted CAR T cells without harming other cells. Technology Validation: Systemic administration of fluorescein-TLR7/8 agonist conjugate in vivo not only rejuvenated exhausted CAR T cells in an immunosuppressive tumor microenvironment without stimulating immune cells in healthy tissues, but also halted the growth of CAR T cell-refractory cancers. Advantages -Non-toxic -Reverses exhausted CAR T cells -Effective therapy for CAR T refractory solid tumors Applications -Solid cancer treatment |
|
|
|
|
Aug 30, 2022
PCT-Patent
WO
(None)
(None)
Aug 30, 2021
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
